His main research concerns Internal medicine, Surgery, Ulcerative colitis, Crohn's disease and Inflammatory bowel disease. His research brings together the fields of Gastroenterology and Internal medicine. He combines subjects such as Adverse effect, Infliximab, Incidence and Cohort study with his study of Surgery.
His studies deal with areas such as Ileitis, Rochester Epidemiology Project and Confidence interval as well as Ulcerative colitis. His Crohn's disease research is multidisciplinary, incorporating perspectives in Immunology, Meta-analysis, Radiology, Colonoscopy and Cohort. His research in Inflammatory bowel disease tackles topics such as Relative risk which are related to areas like Absolute risk reduction.
The scientist’s investigation covers issues in Internal medicine, Gastroenterology, Inflammatory bowel disease, Ulcerative colitis and Crohn's disease. Edward V. Loftus frequently studies issues relating to Surgery and Internal medicine. His study looks at the relationship between Gastroenterology and fields such as Primary sclerosing cholangitis, as well as how they intersect with chemical problems.
The concepts of his Inflammatory bowel disease study are interwoven with issues in Odds ratio and Immunology. His biological study spans a wide range of topics, including Adverse effect, Infliximab, Colitis and Cohort. While the research belongs to areas of Crohn's disease, Edward V. Loftus spends his time largely on the problem of Incidence, intersecting his research to questions surrounding Epidemiology.
His primary scientific interests are in Internal medicine, Ulcerative colitis, Inflammatory bowel disease, Gastroenterology and Crohn's disease. Edward V. Loftus conducts interdisciplinary study in the fields of Internal medicine and In patient through his research. His work is dedicated to discovering how Ulcerative colitis, Tofacitinib are connected with Open label and other disciplines.
His research investigates the connection between Inflammatory bowel disease and topics such as Proportional hazards model that intersect with issues in Hazard ratio. His Gastroenterology research integrates issues from Infliximab, Placebo, Primary sclerosing cholangitis, Antibody and Induction therapy. His Crohn's disease research incorporates elements of Surgery, Abdominal surgery, Incidence and Ustekinumab.
His primary areas of study are Internal medicine, Crohn's disease, Inflammatory bowel disease, Ulcerative colitis and Vedolizumab. His Internal medicine study frequently draws connections between related disciplines such as Gastroenterology. His Crohn's disease research is multidisciplinary, relying on both Young adult, Surgery, Cohort study and C-reactive protein.
The Inflammatory bowel disease study combines topics in areas such as Tumor necrosis factor alpha, Incidence, Epidemiology, Standardized mortality ratio and Proportional hazards model. His Ulcerative colitis study combines topics in areas such as Odds ratio, Colon surgery, Long term safety and Colitis. Edward V. Loftus interconnects Ustekinumab, Retrospective cohort study, Propensity score matching, Severity of illness and Cohort in the investigation of issues within Vedolizumab.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences
Edward V Loftus.
Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology
Mark S. Silverberg;Jack Satsangi;Tariq Ahmad;Ian D. R. Arnott.
Canadian Journal of Gastroenterology & Hepatology (2005)
The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study
William A. Faubion;Edward V. Loftus;William S. Harmsen;Alan R. Zinsmeister.
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
L. Peyrin-Biroulet;W. Sandborn;B. E. Sands;W. Reinisch;W. Reinisch.
The American Journal of Gastroenterology (2015)
The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients
Jean Frederic Colombel;Edward V. Loftus;William J. Tremaine;Laurence J. Egan.
Risk factors for opportunistic infections in patients with inflammatory bowel disease.
Murat Toruner;Edward V. Loftus;W. Scott Harmsen;Alan R. Zinsmeister.
The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota.
David A. Schwartz;Edward V. Loftus;William J. Tremaine;Remo Panaccione.
The Natural History of Adult Crohn's Disease in Population-Based Cohorts
Laurent Peyrin-Biroulet;Edward V. Loftus;Jean Frederic Colombel;William J. Sandborn.
The American Journal of Gastroenterology (2010)
Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000
Conor G. Loftus;Edward V. Loftus;W. Scott Harmsen;Alan R. Zinsmeister.
Inflammatory Bowel Diseases (2007)
Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival.
Edward V. Loftus;Marc D. Silverstein;Marc D. Silverstein;William J. Sandborn;William J. Tremaine.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: